IL-FRISS
13.4.2021 17:05:12 CEST | Business Wire | Press release
FRISS , the market leader in AI-powered fraud, risk and compliance solutions for P&C insurance carriers, today announced the acquisition of Terrene Labs . Industry leaders in providing Commercial Insurance providers with comprehensive Risk Insights, Terrene will be a fundamental addition to the FRISS product family. Commercial lines underwriters now have access to thousands of actionable insights within just 5 seconds, replacing a disjointed manual and limited enrichment process that previously took up to a week and delayed policies for quality customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005837/en/
“We’re bringing commercial lines to the digital age together,” remarked FRISS CEO and Co-founder Jeroen Morrenhof . “True risk insights were always hard to access and we’re changing that. Combined with the analytics capabilities of FRISS, vast data will no longer be so overwhelming – our customers can now make better decisions and they can make them much faster.”
Both the FRISS and Terrene teams distinguish themselves in the marketplace with deep domain knowledge, with over 1,000 years of combined insurance experience. Customers will be able to take advantage of the full end-to-end product suite to screen submissions, policies, endorsement, renewals, book rollovers and claims, utilizing a trove of data sources, images, and social networks, all in real-time through a holistic approach applying predictive analytics and AI.
The acquisition follows FRISS’s announcement of a record year, in which they showed a 58% revenue growth and doubled their client base in North America. By acquiring Terrene, FRISS onboards a market proven product, strong customer base and deep industry knowledge that will strengthen their position as a true industry partner. Terrene products will join the FRISS product suite as Underwriting Insights and will help commercial lines insurers immediately identify every angle of risk. Underwriting Insights will be available immediately as a standalone product, and will soon integrate with the end-to-end solutions already offered by FRISS.
With a singular focus on the insurance industry, FRISS and Terrene tackle all aspects of fraud detection and risk insights respectively. Their offerings are highly synergistic and work seamlessly to solve the issues carriers face in their quest toward end-to-end digital underwriting. Combined, the companies deliver instant protection against unwanted risks, helping revitalize insurance so that carriers can focus on an efficient customer experience without the looming threat of dishonesty.
“Carriers have to be smarter and quicker in the way they assess risk in today’s dynamic environment, and that’s what our team helps them do,” shared Terrene Labs CEO and Founder Piyush Singh . “We’re excited to join the forward-thinking vision of the FRISS team to accelerate the mission to solve our customers’ most pressing issues together.”
To learn more about FRISS Underwriting insights and watch a quick demo here .
About Terrene Labs
Led by a team of industry experts, Terrene provides solutions for next-generation digital underwriting. Turning a manual, multi-day process into an automated solution that arrives in seconds, Terrene takes the chore out of an underwriter’s job and allows them to focus on the tasks that really matter. Terrene customers appreciate the long-term value of instantly understanding every risk in their book of business, proven through the loyalty and strong relationship of their customer base.
About FRISS
With over 200 implementations, FRISS is recognized globally as the leading provider of AI-powered fraud detection and prevention software for the P&C industry. As the longest operating dedicated provider, FRISS has diligently evolved to meet the changing needs of their customers, especially as the industry enters the accelerated change of the digital age of insurance. No other company offers the depth of experience and holistic focus on fraud detection and prevention found at FRISS. FRISS customers appreciate their unique focus on insurance fraud prevention and the dedication they show to their customers’ success. Learn more at www.friss.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005837/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom